Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR20013 vs fosaprepitant + palonosetron for prevention of ADC-induced nausea and vomiting
ChiCTR2600127254Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rolapitant + palonosetron in nausea ((none)), Vomiting and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Complete response rate on Days 1–14 of ADC treatment. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
rolapitant + palonosetron
03
Conditions
nausea ((none))Vomitingchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2600127254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127254.